A promising title for Cenexi, in The Parmaceutical Post magazine from October 2021.
In the dossier on Challenges of new therapies, Cenexi sets out its innovation momentum on page 68, driven by Crossject and Ose Immunotherapeutics projects.
This article follows an interview with President Christophe DURAND.
The 100-pages magazine available by subscription in its paper version is also accessible by downloading the PDF in the link below.
Enjoy your reading!